Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods

There is significant variation in the use of polymyxin B (PMB), and optimal dosing has not been defined. The purpose of this retrospective study was to evaluate the relationship between PMB dose and clinical outcomes. We included patients with bloodstream infections (BSIs) due to carbapenem-resistan...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Nelson, Brian C., Eiras, Daniel P., Gomez-Simmonds, Angela, Loo, Angela S., Satlin, Michael J., Jenkins, Stephen G., Whittier, Susan, Calfee, David P., Furuya, E. Yoko, Kubin, Christine J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2015
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604419/
https://ncbi.nlm.nih.gov/pubmed/26324272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00844-15
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak